Literature DB >> 18368302

Current pharmacologic treatment for orthostatic hypotension.

Roy Freeman1.   

Abstract

Orthostatic hypotension is treated effectively with the combined use of non-pharmacological and pharmacological interventions. Patients should be counseled as to the nature of the underlying disorder and reversible causes of orthostatic hypotension should be removed. Should symptoms persist, pharmacological treatment is implemented. First line pharmacotherapeutic interventions include volume repletion in combination with alpha-adrenoreceptor agonists. If unsuccessful there are several supplementary agents with different mechanisms of action that may provide an additive effect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18368302     DOI: 10.1007/s10286-007-1003-1

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN: 0959-9851            Impact factor:   4.435


  41 in total

1.  Paradoxical pressor effects of beta-blockers in standing elderly patients with mild hypertension: a beneficial side effect.

Authors:  T J Cleophas; I Grabowsky; M G Niemeyer; W M Mäkel; E E van der Wall
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

2.  Corticosteroids in the management of orthostatic hypotension.

Authors:  I J Schatz; M J Miller; B Frame
Journal:  Cardiology       Date:  1976       Impact factor: 1.869

3.  The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure.

Authors:  C J Mathias; P Fosbraey; D F da Costa; A Thornley; R Bannister
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-09

4.  Comparative effects of clonidine and dihydroergotamine on venomotor tone and orthostatic tolerance in patients with severe hypoadrenergic orthostatic hypotension.

Authors:  Ronald G Victor; William T Talman
Journal:  Am J Med       Date:  2002-04-01       Impact factor: 4.965

5.  Hemodynamic and humoral effects of caffeine in autonomic failure. Therapeutic implications for postprandial hypotension.

Authors:  J Onrot; M R Goldberg; I Biaggioni; A S Hollister; D Kingaid; D Robertson
Journal:  N Engl J Med       Date:  1985-08-29       Impact factor: 91.245

6.  Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension.

Authors:  F M Fouad-Tarazi; M Okabe; H Goren
Journal:  Am J Med       Date:  1995-12       Impact factor: 4.965

7.  Clonidine raises blood pressure in severe idiopathic orthostatic hypotension.

Authors:  D Robertson; M R Goldberg; A S Hollister; D Wade; R M Robertson
Journal:  Am J Med       Date:  1983-02       Impact factor: 4.965

8.  Observations on haematological and cardiovascular effects of erythropoietin treatment in multiple system atrophy with sympathetic failure.

Authors:  Andrea Sylvia Winkler; Sabine Landau; Peter Watkins; K Ray Chaudhuri
Journal:  Clin Auton Res       Date:  2002-06       Impact factor: 4.435

9.  Effect of xamoterol in Shy-Drager syndrome.

Authors:  A Obara; H Yamashita; S Onodera; O Yahara; H Honda; N Hasebe
Journal:  Circulation       Date:  1992-02       Impact factor: 29.690

10.  A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension.

Authors:  R A Wright; H C Kaufmann; R Perera; T L Opfer-Gehrking; M A McElligott; K N Sheng; P A Low
Journal:  Neurology       Date:  1998-07       Impact factor: 9.910

View more
  11 in total

1.  Management of common adverse effects of antipsychotic medications.

Authors:  T Scott Stroup; Neil Gray
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

2.  The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale.

Authors:  Horacio Kaufmann; Richard Malamut; Lucy Norcliffe-Kaufmann; Kathleen Rosa; Roy Freeman
Journal:  Clin Auton Res       Date:  2011-11-02       Impact factor: 4.435

Review 3.  Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management.

Authors:  James J Gugger
Journal:  CNS Drugs       Date:  2011-08       Impact factor: 5.749

Review 4.  Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

5.  Low iron storage and mild anemia in postural tachycardia syndrome in adolescents.

Authors:  Imad T Jarjour; Laila K Jarjour
Journal:  Clin Auton Res       Date:  2013-05-30       Impact factor: 4.435

Review 6.  Serotonergic receptor gene polymorphism and response to selective serotonin reuptake inhibitors in ethnic Malay patients with first episode of major depressive disorder.

Authors:  Ibrahim Mohammed Badamasi; Munn Sann Lye; Normala Ibrahim; Nurul Asyikin Abdul Razaq; King Hwa Ling; Johnson Stanslas
Journal:  Pharmacogenomics J       Date:  2021-03-17       Impact factor: 3.550

7.  Use of fludrocortisone for intradialytic hypotension.

Authors:  Yuri Seo; Soomin Jeung; Sun-Myoung Kang; Won Seok Yang; Hyosang Kim; Soon Bae Kim
Journal:  Kidney Res Clin Pract       Date:  2018-03-31

8.  Normalization of Blood Pressure With Spinal Cord Epidural Stimulation After Severe Spinal Cord Injury.

Authors:  Susan J Harkema; Siqi Wang; Claudia A Angeli; Yangsheng Chen; Maxwell Boakye; Beatrice Ugiliweneza; Glenn A Hirsch
Journal:  Front Hum Neurosci       Date:  2018-03-08       Impact factor: 3.169

Review 9.  Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management.

Authors:  Manuela Metzler; Susanne Duerr; Roberta Granata; Florian Krismer; David Robertson; Gregor K Wenning
Journal:  J Neurol       Date:  2012-11-20       Impact factor: 4.849

10.  Epidural Spinal Cord Stimulation of Lumbosacral Networks Modulates Arterial Blood Pressure in Individuals With Spinal Cord Injury-Induced Cardiovascular Deficits.

Authors:  Sevda C Aslan; Bonnie E Legg Ditterline; Michael C Park; Claudia A Angeli; Enrico Rejc; Yangsheng Chen; Alexander V Ovechkin; Andrei Krassioukov; Susan J Harkema
Journal:  Front Physiol       Date:  2018-05-18       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.